MAP2K7 and neoplasm: As expected, Rat1-myr-p110α tumors showed slight tumor regression upon treatment at the reported efficacious dose level of the PI3K inhibitor GDC0941 (T/C = −3%), but tumors did not regress upon treatment with the MEK inhibitor AZD6244 (T/C = 29%) [36].